[Summary] Consolidated Financial Results for the Six Months Ended September 30, 2025 (Under Japanese GAAP)11/14TDnetPDF(98KB)
Notice Concerning Additional Contribution for Continuation of Performance-Linked Stock Compensation System11/14TDnetPDF(106KB)
Notice Concerning Establishment of Medical Equipment Subsidiary, Simplified Absorption-type Company Split, and Transfer of Subsidiary Shares9/2TDnetPDF(193KB)
[Summary] Consolidated Financial Results for the Three Months Ended June 30, 2025 (Under Japanese GAAP)8/13TDnetPDF(292KB)
Notice Concerning Recording of Extraordinary Losses (Loss on Valuation of Investment Securities) 5/15TDnetPDF(103KB)
Notice Concerning Continuation and Partial Revision of Performance-Linked Stock Compensation System5/15TDnetPDF(135KB)
[Summary] Consolidated Financial Results for the Fiscal Year Ended March 31, 2025 (Under Japanese GAAP)5/15TDnetPDF(364KB)